EP0946733A4 - Hsv/aav hybrid amplicon vectors - Google Patents

Hsv/aav hybrid amplicon vectors

Info

Publication number
EP0946733A4
EP0946733A4 EP97946914A EP97946914A EP0946733A4 EP 0946733 A4 EP0946733 A4 EP 0946733A4 EP 97946914 A EP97946914 A EP 97946914A EP 97946914 A EP97946914 A EP 97946914A EP 0946733 A4 EP0946733 A4 EP 0946733A4
Authority
EP
European Patent Office
Prior art keywords
vector system
hsv
mitotic
expressing
aav hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97946914A
Other languages
German (de)
French (fr)
Other versions
EP0946733A1 (en
Inventor
Xandra O Breakefield
David R Jacoby
Frances I Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP0946733A1 publication Critical patent/EP0946733A1/en
Publication of EP0946733A4 publication Critical patent/EP0946733A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pretreatment Of Seeds And Plants (AREA)

Abstract

The present invention relates to a hybrid vector system which incorporates elements of herpesvirus and adeno-associated virus which are capable of expressing a gene product in eukaryotic cells. The vector system of the present invention provides a means of packaging plasmid DNA into highly infectious virions which can efficiently and safely deliver large transgenes to both mitotic and postmitotic cells in a state which can be maintained for extended periods. The invention pertains to the use of this vector system in introducing and expressing gene sequences in mitotic and postmitotic cells for therapeutic purposes.
EP97946914A 1996-11-12 1997-11-12 Hsv/aav hybrid amplicon vectors Withdrawn EP0946733A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74791996A 1996-11-12 1996-11-12
US747919 1996-11-12
PCT/US1997/020422 WO1998021345A1 (en) 1996-11-12 1997-11-12 Hsv/aav hybrid amplicon vectors

Publications (2)

Publication Number Publication Date
EP0946733A1 EP0946733A1 (en) 1999-10-06
EP0946733A4 true EP0946733A4 (en) 2003-01-08

Family

ID=25007248

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97946914A Withdrawn EP0946733A4 (en) 1996-11-12 1997-11-12 Hsv/aav hybrid amplicon vectors

Country Status (5)

Country Link
EP (1) EP0946733A4 (en)
JP (1) JP2002503086A (en)
AU (1) AU734063B2 (en)
CA (1) CA2271777A1 (en)
WO (1) WO1998021345A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677155B1 (en) 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
WO2000065077A1 (en) * 1999-04-22 2000-11-02 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
WO2001005229A1 (en) * 1999-07-15 2001-01-25 The General Hospital Corporation Non-defective epstein-barr viral vector
DE10137283A1 (en) * 2001-08-01 2003-02-27 Deutsches Krebsforsch AAV vector packaging plasmids for helper virus-free production of pseudotyped AAV particles by single transfection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PECHAN P A ET AL: "A novel 'piggyback' packaging system for herpes simplex virus amplicon vectors.", HUMAN GENE THERAPY. UNITED STATES 20 OCT 1996, vol. 7, no. 16, 20 October 1996 (1996-10-20), pages 2003 - 2013, XP001107052, ISSN: 1043-0342 *
ROBBINS P D ET AL: "VIRAL VECTORS FOR GENE THERAPY", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 80, no. 1, 1998, pages 35 - 47, XP002927113, ISSN: 0163-7258 *
See also references of WO9821345A1 *

Also Published As

Publication number Publication date
AU734063B2 (en) 2001-05-31
AU5199998A (en) 1998-06-03
CA2271777A1 (en) 1998-05-22
WO1998021345A1 (en) 1998-05-22
EP0946733A1 (en) 1999-10-06
JP2002503086A (en) 2002-01-29

Similar Documents

Publication Publication Date Title
CA2145535A1 (en) Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
CA2311643A1 (en) Compositions and methods for inducing gene expression
WO1998027204A3 (en) AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
EP0851769A4 (en) Gene therapy using ovine adenoviral vectors
IL122403A0 (en) Recombinant dna vector comprising aav nucleic acid sequences
AU5464000A (en) Recombinant adenoviral vectors for cell specific infection and genome integration and expressing chimeric fiber proteins
WO2000034497A3 (en) Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
CA2228635A1 (en) Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods
WO1998056937A3 (en) Chimeric vectors comprising a phage packaging site and a portion derived from the genome of a eukaryotic virus
WO1998044097A3 (en) Method for enhancing expression of a foreign or endogenous gene product in plants
HK1018078A1 (en) Recombinant sendai virus
AU3150495A (en) Dna sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
CA2047290A1 (en) Recombinant marek's disease virus
WO1998039463A3 (en) Lentivirus based vector and vector system
WO1997005255A3 (en) Helper viruses for preparing recombinant viral vectors
IL122206A0 (en) Adeno-associated virus vectors for gene expression
EP1041142A3 (en) Universal donor cells
AU716500B2 (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs
AU1674697A (en) Vectors and methods for providing cells with additional nucleic acid material integrated in the genome of said cells
AU5551996A (en) An adenovirus helper-virus system
SI0632129T1 (en) Recombinant foamy virus vectors for medicinal and diagnostic uses, and processes for preparing recombinant foamy virus vectors
WO1998055639A3 (en) Recombinant adenoviral vectors comprising a splicing sequence
AU3919997A (en) Nucleic acid constructs containing hybrid promoters for use in gene therapy
EP0946733A4 (en) Hsv/aav hybrid amplicon vectors
Burton et al. Replication-defective genomic herpes simplex vectors: design and production

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

R17P Request for examination filed (corrected)

Effective date: 19990610

A4 Supplementary search report drawn up and despatched

Effective date: 20021125

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030404

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030815